Progenics Pharmaceuticals Inc. (PGNX)

4.29
0.21 4.67
NASDAQ : Health Technology
Prev Close 4.50
Open 4.47
Day Low/High 4.10 / 4.55
52 Wk Low/High 3.42 / 8.11
Volume 1.48M
Avg Volume 769.40K
Exchange NASDAQ
Shares Outstanding 86.42M
Market Cap 333.59M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Progenics Pharmaceuticals Announces Additional Governance Enhancements

Progenics Pharmaceuticals Announces Additional Governance Enhancements

Board Accepts Resignations of Directors Peter J. Crowley and Michael D.

CMS Grants New Technology Add-On Payment For Inpatient Use Of AZEDRA® (iobenguane I 131)

CMS Grants New Technology Add-On Payment For Inpatient Use Of AZEDRA® (iobenguane I 131)

Provides Additional Medicare Reimbursement up to 65% of the Cost of AZEDRA Prescribed for Inpatient Medicare Patients

Progenics Pharmaceuticals Shares Cross Below 200 DMA

Progenics Pharmaceuticals Shares Cross Below 200 DMA

In trading on Monday, shares of Progenics Pharmaceuticals, Inc. crossed below their 200 day moving average of $4.83, changing hands as low as $4.72 per share.

Progenics Pharmaceuticals Completes Enrollment In Pivotal Phase 3 CONDOR Study Of PyL For The Detection Of Prostate Cancer

Progenics Pharmaceuticals Completes Enrollment In Pivotal Phase 3 CONDOR Study Of PyL For The Detection Of Prostate Cancer

Top-line Data Now Expected by Year End Reaches Alignment with FDA on Regulatory Path; Company to Submit NDA Following Positive CONDOR Data Completed Enrollment in Pivotal Phase 3 Trial in Eight Months NEW YORK, Aug.

Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results And Business Update Call For August 9

Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results And Business Update Call For August 9

NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.

Progenics Pharmaceuticals Announces Collaboration With Veterans Affairs On The AI Research Program For Medical Image Analysis

Progenics Pharmaceuticals Announces Collaboration With Veterans Affairs On The AI Research Program For Medical Image Analysis

The collaboration with VA Greater Los Angeles Healthcare System is nation's first to validate deep learning algorithms in medical imaging of veterans with prostate cancer

Velan Announces Progenics Pharmaceuticals Stockholders Support Its Campaign For Change At Progenics' 2019 Annual Meeting

Velan Announces Progenics Pharmaceuticals Stockholders Support Its Campaign For Change At Progenics' 2019 Annual Meeting

Final Voting Results Confirm that Approximately Two-Thirds of the Votes Cast Were Against the Re-Election of Peter Crowley and Michael Kishbauch

Following These 2 Small-Caps Into Earnings

Following These 2 Small-Caps Into Earnings

I'm looking forward to hearing from Progenics Pharmaceuticals and Builders FirstSource.

Progenics Announces Preliminary Voting Results Of Annual Meeting Of Shareholders

Progenics Announces Preliminary Voting Results Of Annual Meeting Of Shareholders

Commences Search Process to Identify New Board Candidates, Welcomes Input from All Shareholders

Velan Reminds Stockholders To Follow ISS' Recommendation By Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley And Michael Kishbauch

Velan Reminds Stockholders To Follow ISS' Recommendation By Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley And Michael Kishbauch

Agrees with ISS that "Board Level Change is Warranted, With the Ultimate Goal of Enhancing Shareholder Board Oversight"

Progenics Pharmaceuticals Strengthens Management Team With Appointment Of Huw Jones As Vice President, Commercial

Progenics Pharmaceuticals Strengthens Management Team With Appointment Of Huw Jones As Vice President, Commercial

-Commercial Leader Brings Deep Experience in Radiopharmaceuticals and Oncology-

Velan Urges Stockholders To Follow ISS' Recommendation By Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley And Michael Kishbauch

Velan Urges Stockholders To Follow ISS' Recommendation By Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley And Michael Kishbauch

Agrees with ISS that the Board's Focus Should Be on Why Shareholder Returns Have Been Weak and Why Progenics has "Experienced Recent, Significant Delays in Both Drug Development and Commercialization"

ISS Supports Velan's Call For Change By Recommending Stockholders Vote "Against" Progenics Pharmaceuticals Directors Peter Crowley And Michael Kishbauch

ISS Supports Velan's Call For Change By Recommending Stockholders Vote "Against" Progenics Pharmaceuticals Directors Peter Crowley And Michael Kishbauch

ISS Believes Velan Presented a "Compelling Argument that Board Level Change is Warranted" to Enhance "Shareholder Board Oversight"

Velan Clarifies Interactions With Progenics Pharmaceuticals' Board Of Directors

Velan Clarifies Interactions With Progenics Pharmaceuticals' Board Of Directors

Highlights how the Board Continues to Distort the Truth and Mislead Stockholders in an Attempt to Preserve the Troubling Status Quo and Avoid Accountability at All Costs

Interesting PGNX Put And Call Options For February 2020

Interesting PGNX Put And Call Options For February 2020

Investors in Progenics Pharmaceuticals, Inc. saw new options begin trading this week, for the February 2020 expiration.

Velan Releases Presentation Reiterating The Facts And Setting The Record Straight For Progenics Pharmaceuticals' Stockholders

Velan Releases Presentation Reiterating The Facts And Setting The Record Straight For Progenics Pharmaceuticals' Stockholders

Highlights How the Board is Distorting the Truth, Mischaracterizing the Company's Current Dire State and Misleading Stockholders in an Attempt to Preserve the Troubling Status Quo

Velan Releases Detailed Presentation On Progenics Pharmaceuticals

Velan Releases Detailed Presentation On Progenics Pharmaceuticals

Details the Persistent Performance, Execution, Governance and Transparency Shortcomings that Have Led to the Destruction of Significant Value

PGNX Crosses Above Key Moving Average Level

PGNX Crosses Above Key Moving Average Level

In trading on Thursday, shares of Progenics Pharmaceuticals, Inc. crossed above their 200 day moving average of $4.99, changing hands as high as $5.07 per share.

Velan Calls On Progenics Pharmaceuticals' Board To Back Up Recent Claims

Velan Calls On Progenics Pharmaceuticals' Board To Back Up Recent Claims

Actual Stockholders, the True Owners of the Company, Deserve Answers and Clarity

Velan Sets The Record Straight On Progenics Pharmaceuticals' Latest Misleading Statements

Velan Sets The Record Straight On Progenics Pharmaceuticals' Latest Misleading Statements

Highlights the Multiple Ways Peter Crowley and Michael Kishbauch have Failed Stockholders While the Board Disingenuously Touts its "Significant Progress" and Self-Proclaimed Mastery

Velan Capital Sends Letter To Stockholders Calling Out Progenics Pharmaceuticals' Board For Unnecessarily Diluting Stockholders To Support Outsized And Undeserved Compensation

Velan Capital Sends Letter To Stockholders Calling Out Progenics Pharmaceuticals' Board For Unnecessarily Diluting Stockholders To Support Outsized And Undeserved Compensation

Oops, They Did it Again - Last Week the Board Chose to Further Dilute Stockholders, Proving Toxic Misalignment of Interests

Velan Responds To Progenics Pharmaceuticals' Misleading Statements

Velan Responds To Progenics Pharmaceuticals' Misleading Statements

Clarifies that the Board is Not a "Fellow Shareholder" and Expresses Concern with the Misalignment of Interests with Progenics Stockholders

Velan Files Definitive Proxy Materials In Connection With Progenics Pharmaceuticals 2019 Annual Meeting Of Stockholders

Velan Files Definitive Proxy Materials In Connection With Progenics Pharmaceuticals 2019 Annual Meeting Of Stockholders

Sends Letter to Fellow Stockholders Detailing the Persistent Performance, Execution, Accountability, Governance and Transparency Shortcomings that Have Led to the Destruction of Significant Value

Interesting PGNX Put And Call Options For July 19th

Interesting PGNX Put And Call Options For July 19th

Investors in Progenics Pharmaceuticals, Inc. saw new options begin trading this week, for the July 19th expiration.

Velan Implores For Improved Transparency And Real Change At Progenics Pharmaceuticals Following Q1 2019 Earnings Call

Velan Implores For Improved Transparency And Real Change At Progenics Pharmaceuticals Following Q1 2019 Earnings Call

Believes Progenics Board and Senior Management Continue to Fail at Explaining Poor Performance and Instead, Hide Behind Insufficient Disclosure

Velan Calls For Increased Transparency At Progenics Pharmaceuticals During Q1 Earnings Call

Velan Calls For Increased Transparency At Progenics Pharmaceuticals During Q1 Earnings Call

Filed Preliminary Proxy Materials Seeking Stockholder Support Against the Election of Peter J. Crowley and Michael D. Kishbauch at the Company's 2019 Annual Meeting to Send a Clear Message that Meaningful Change is Required

Velan Delivers Letter To The Board Of Progenics Pharmaceuticals

Velan Delivers Letter To The Board Of Progenics Pharmaceuticals

Expresses Serious Concerns with the Company's Persistent Underperformance and Destruction of Stockholder Value

TheStreet Quant Rating: D (Sell)